1. Search Result
Search Result
Results for "

Ces Inhibitors

" in MCE Product Catalog:
Cat. No. Product Name Target Research Areas
  • HY-110148
    WWL113

    Others Metabolic Disease
    WWL113 is a selective and orally active Ces3 and Ces1f inhibitor, with IC50 values of 120 nM and 100 nM for Ces3 and Ces1f, respectively. WWL113 appears to show excellent selectivity for the 60-kDa serine hydrolase (or hydrolases).
  • HY-112423
    CE-245677

    Trk Receptor Cancer Cardiovascular Disease
    CE-245677 is a potent reversible inhibitor of Tie2 and TrkA/B kinases with a cellular IC50s of 4.7 and 1 nM.
  • HY-108539A
    (R)-CE3F4

    Ras Metabolic Disease
    (R)-CE3F4 is a potent and selective inhibitor of exchange protein directly activated by cAMP isoform 1 (Epac1), with an IC50 of 4.2 μM, with 10-fold selectivity for Epac1 over Epac2 (IC50, 44 μM). (R)-CE3F4 is more potent than racemic CE3F4 and (S)-CE3F4.
  • HY-118284
    Vicagrel

    P2Y Receptor Cardiovascular Disease
    Vicagrel, an acetate derivative of Clopidogrel, is a P2Y12 platelet inhibitor potentially for the treatment of thrombosis, the substrate of carboxylesterase 2 (CES2). Vicagrel demonstrates a favorable safety profile and excellent anti-platelet activity, which could be an anti-platelet drug and for the unmet medical needs of cardiovascular diseases.
  • HY-120602
    WWL229

    Others Metabolic Disease
    WWL229 is a selective inhibitor of carboxylesterase 3 (Ces3) with an IC50 of 1.94 µM. WWL229 promotes lipid storage in cultured adipocytes and prevents basal lipolysis.
  • HY-147763
    HCV-IN-39

    HCV Infection
    HCV-IN-39 (Compound 18a) is a potent hepatitis C virus (HCV) nucleoside inhibitor with EC50 values of 0.644, 0.952 and 0.154 μM against GT1a, GT1b and GT1b CES1 replicons.
  • HY-147764
    HCV-IN-40

    HCV Infection
    HCV-IN-40 (Compound 18c) is a potent, orally active hepatitis C virus (HCV) nucleoside inhibitor with EC50 values of 0.259, 0.434 and 0.069 μM against GT1a, GT1b and GT1b CES1 replicons.